Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.65 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2881016 | 0.87 | ALDH1A1 (0.64) | ACLYAKR1C3ALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL2875837 | 0.83 | LMNA (0.55) | ALDH1A1SMN1; SMN2LMNAGLA | |
| SCHEMBL22000024 | 0.79 | ACLY (1.00) | ACLYAKR1C3ALDH1A1SMN1; SMN2CHRM2 | |
| SCHEMBL2877986 | 0.78 | CA12 (0.54) | ALDH1A1SMN1; SMN2MAPTPOLBCA1 | |
| SCHEMBL2875520 | 0.77 | ACLY (0.54) | ACLYAKR1C3ALDH1A1SMN1; SMN2CHRM2 | |
| SCHEMBL3409768 | 0.76 | GSTO1 (0.62) | ALDH1A1SMN1; SMN2RAB9AMAPTPOLB | |
| SCHEMBL22489819 | 0.76 | TAAR1 (0.48) | ACLYALDH1A1CNR1LMNA | |
| SCHEMBL2880609 | 0.76 | ALDH1A1 (0.56) | ALDH1A1POLBLMNAGLA | |
| SCHEMBL9813024 | 0.75 | AKR1C3 (0.76) | ACLYAKR1C3ALDH1A1SMN1; SMN2CHRM2 | |
| SCHEMBL12721426 | 0.75 | CHRM2 (0.64) | ACLYAKR1C3ALDH1A1SMN1; SMN2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066628-B1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | SANOFI AVENTIS (FR) | 2010-10-20 | — | — | EP | disclosed |
| US-20090176804-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2009-07-09 | — | — | US | disclosed |
| EP-2066628-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | Sanofi-Aventis (FR) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008014186-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176804-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | PTGER2, PTGDR2, CYSLTR2 | ACLY 4136/4885AKR1C3 1702/4885ALDH1A1 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.